High Tide Reports Q2 Earnings Beat, Shares Surge 21%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2026
0mins
Source: seekingalpha
- Record Revenue: High Tide reported a record revenue of C$179.3 million for Q2 FY2026, reflecting a 30% year-over-year increase and surpassing estimates of C$171.15 million, indicating strong performance in the retail sector.
- Stable Market Share: Canna Cabana maintained a 12% market share, and excluding British Columbia's restrictions, its share increased to 14%, up from 13% last year, demonstrating robust growth in a competitive market.
- Improved Profitability: Adjusted EBITDA reached a record C$13.9 million, a 73% year-over-year increase and the fastest growth in nine quarters, despite having three fewer days in the quarter, showcasing effective cost control and operational efficiency.
- Medical Cannabis Distribution Growth: Remexian achieved a record distribution of 7.6 tonnes of medical cannabis in Germany, marking a 49% year-over-year and 21% sequential increase, further solidifying High Tide's position in the international market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HITI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HITI
Wall Street analysts forecast HITI stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.280
Low
7.50
Averages
7.50
High
7.50
Current: 2.280
Low
7.50
Averages
7.50
High
7.50
About HITI
High Tide Inc. is a retail-focused cannabis company. The Company’s segments include bricks-and-mortar, e-commerce and medical cannabis distribution. Its Bricks-and-mortar segment includes the Company’s Canadian bricks-and-mortar locations. Its E-commerce segment includes the Company’s United States and international subsidiaries and supports the distribution of accessories and other items to the United States. The medical cannabis distribution segment includes the medical cannabis distribution operations. It offers a suite of proprietary brands which include Dopezilla, Atomik, Puff Puff Pass, Vodka Glass, Queen of Bud, and Cabana Cannabis Co. Canna Cabana is the Company’s primary retail cannabis business, offering the retail sale of various cannabis products and accessories through its provincially authorized cannabis retail store locations. Canna Cabana operates a retail cannabis chain with approximately 219 branded stores operating across Canada.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
High Tide Showcases Medical Cannabis Partnerships in Germany
- Market Expansion: High Tide's subsidiary Remexian showcased exclusive medical cannabis distribution partnerships with several Canadian brands at the 2026 Mary Jane Berlin trade show, further solidifying its leading position in Germany's rapidly growing medical cannabis market.
- Diverse Product Portfolio: Remexian highlighted medical cannabis products from brands like Tribal and Highly Dutch Organic, emphasizing its expanding portfolio of exclusive distribution agreements that connect directly with pharmacies and healthcare professionals in Germany, addressing patient demand for high-quality products.
- Positive Industry Response: The event garnered positive feedback from patients and healthcare professionals, indicating a rising demand for high-quality, trusted cannabis products, which enhances Remexian's competitive edge in the market.
- Strategic Investment: By continuously broadening its product offerings and strengthening supply chain relationships, Remexian aims to capture a larger share of one of the world's most attractive medical cannabis markets, showcasing High Tide's strategy of leveraging its Canadian strengths for global diversification.
See More
High Tide Showcases Medical Cannabis Partnerships in Germany
- Market Expansion: High Tide's subsidiary Remexian showcased exclusive medical cannabis distribution partnerships with several Canadian brands at the 2026 Mary Jane Berlin trade show, further solidifying its leading position in Germany's rapidly growing medical cannabis market.
- Diverse Product Portfolio: Remexian highlighted medical cannabis products from brands like Tribal and Highly Dutch Organic, emphasizing its expanding portfolio of exclusive distribution agreements that connect Canadian brands directly with pharmacies and healthcare professionals in Germany.
- Industry Opportunities: Germany is viewed as a significant growth opportunity in the global medical cannabis industry, and Remexian's participation not only enhances its reputation as a trusted importer of premium products but also fosters relationships with healthcare professionals, facilitating the expansion of its pharmacy network.
- Competitive Advantage: High Tide's CEO Raj Grover stated that by continuously broadening its product offerings and strengthening supply chain relationships, Remexian is positioning itself to capture a larger share of one of the world's most attractive medical cannabis markets, showcasing its unique procurement capabilities and market strategy.
See More
High Tide Inc Reports Record Q2 Earnings with 30% Revenue Growth
- Significant Revenue Growth: High Tide Inc reported a record revenue of $179.3 million in Q2, reflecting a 30% year-over-year increase, marking the fastest growth rate in 11 quarters and indicating strong market performance and expansion potential.
- Record Gross Margin: The company achieved a gross profit of $48.4 million with a gross margin of 27%, the highest in eight quarters, showcasing improved profitability in its medical cannabis distribution segment, particularly in the German market.
- Strong Membership Growth: Cabana Club membership reached 2.65 million, up 39% year-over-year, with elite memberships soaring by 84%, which not only enhances customer loyalty but also lays a solid foundation for future sales growth.
- Enhanced Financial Flexibility: High Tide secured a $40 million credit facility with Bank of Montreal, boosting its financial flexibility; despite free cash flow being $1.5 million, the company is actively investing to support future expansion plans.
See More
High Tide Reports Q2 Earnings Beat, Shares Surge 21%
- Record Revenue: High Tide reported a record revenue of C$179.3 million for Q2 FY2026, reflecting a 30% year-over-year increase and surpassing estimates of C$171.15 million, indicating strong performance in the retail sector.
- Stable Market Share: Canna Cabana maintained a 12% market share, and excluding British Columbia's restrictions, its share increased to 14%, up from 13% last year, demonstrating robust growth in a competitive market.
- Improved Profitability: Adjusted EBITDA reached a record C$13.9 million, a 73% year-over-year increase and the fastest growth in nine quarters, despite having three fewer days in the quarter, showcasing effective cost control and operational efficiency.
- Medical Cannabis Distribution Growth: Remexian achieved a record distribution of 7.6 tonnes of medical cannabis in Germany, marking a 49% year-over-year and 21% sequential increase, further solidifying High Tide's position in the international market.
See More
High Tide Reports Strong Q2 Results with Record Revenue
- Record Revenue: High Tide's German medical cannabis subsidiary, Remexian Pharma GmbH, achieved record revenue of $31.6 million in Q2 2026, demonstrating strong growth potential in the medical cannabis market and further solidifying its market position.
- Margin Improvement: Remexian's gross margins increased to 27%, reflecting effective cost control and successful strategies in product pricing and market demand, thereby enhancing overall profitability.
- Positive Free Cash Flow: The company reported positive free cash flow, indicating strong operational efficiency and financial health, which provides funding support for future expansions and investments, boosting investor confidence.
- Financial Transparency: High Tide released unaudited financial statements for the period ending April 30, 2026, ensuring financial transparency and enhancing market trust in its long-term growth strategy.
See More
High Tide Reports Record Revenue and Growth in Q2 2026
- Record Revenue: High Tide achieved a record revenue of CAD 179.3 million in Q2 2026, reflecting a 30% year-over-year increase, marking the fastest growth rate in 11 quarters and demonstrating strong performance in both Canadian and German markets.
- Medical Cannabis Growth: Remexian Pharma GmbH generated record revenue of CAD 31.6 million from medical cannabis sales in Germany, with gross margins increasing to 27%, indicating that the company's market share has now exceeded 14%, laying a solid foundation for future expansion.
- Positive Free Cash Flow: Although free cash flow was CAD 1.5 million, down from CAD 4.9 million last year, the company reported strong operating cash flow of CAD 8.8 million, showcasing its ongoing financial health and growth potential.
- Significant Membership Growth: Cabana Club membership has surpassed 2.65 million, up 39% year-over-year, while ELITE membership reached 178,000, an 84% increase, indicating continued improvement in customer loyalty and market share.
See More
High Tide Showcases Medical Cannabis Partnerships in Germany
- Market Expansion: High Tide's subsidiary Remexian showcased exclusive medical cannabis distribution partnerships with several Canadian brands at the 2026 Mary Jane Berlin trade show, further solidifying its leading position in Germany's rapidly growing medical cannabis market.
- Diverse Product Portfolio: Remexian highlighted medical cannabis products from brands like Tribal and Highly Dutch Organic, emphasizing its expanding portfolio of exclusive distribution agreements that connect directly with pharmacies and healthcare professionals in Germany, addressing patient demand for high-quality products.
- Positive Industry Response: The event garnered positive feedback from patients and healthcare professionals, indicating a rising demand for high-quality, trusted cannabis products, which enhances Remexian's competitive edge in the market.
- Strategic Investment: By continuously broadening its product offerings and strengthening supply chain relationships, Remexian aims to capture a larger share of one of the world's most attractive medical cannabis markets, showcasing High Tide's strategy of leveraging its Canadian strengths for global diversification.
See More
High Tide Showcases Medical Cannabis Partnerships in Germany
- Market Expansion: High Tide's subsidiary Remexian showcased exclusive medical cannabis distribution partnerships with several Canadian brands at the 2026 Mary Jane Berlin trade show, further solidifying its leading position in Germany's rapidly growing medical cannabis market.
- Diverse Product Portfolio: Remexian highlighted medical cannabis products from brands like Tribal and Highly Dutch Organic, emphasizing its expanding portfolio of exclusive distribution agreements that connect Canadian brands directly with pharmacies and healthcare professionals in Germany.
- Industry Opportunities: Germany is viewed as a significant growth opportunity in the global medical cannabis industry, and Remexian's participation not only enhances its reputation as a trusted importer of premium products but also fosters relationships with healthcare professionals, facilitating the expansion of its pharmacy network.
- Competitive Advantage: High Tide's CEO Raj Grover stated that by continuously broadening its product offerings and strengthening supply chain relationships, Remexian is positioning itself to capture a larger share of one of the world's most attractive medical cannabis markets, showcasing its unique procurement capabilities and market strategy.
See More
High Tide Inc Reports Record Q2 Earnings with 30% Revenue Growth
- Significant Revenue Growth: High Tide Inc reported a record revenue of $179.3 million in Q2, reflecting a 30% year-over-year increase, marking the fastest growth rate in 11 quarters and indicating strong market performance and expansion potential.
- Record Gross Margin: The company achieved a gross profit of $48.4 million with a gross margin of 27%, the highest in eight quarters, showcasing improved profitability in its medical cannabis distribution segment, particularly in the German market.
- Strong Membership Growth: Cabana Club membership reached 2.65 million, up 39% year-over-year, with elite memberships soaring by 84%, which not only enhances customer loyalty but also lays a solid foundation for future sales growth.
- Enhanced Financial Flexibility: High Tide secured a $40 million credit facility with Bank of Montreal, boosting its financial flexibility; despite free cash flow being $1.5 million, the company is actively investing to support future expansion plans.
See More
High Tide Reports Q2 Earnings Beat, Shares Surge 21%
- Record Revenue: High Tide reported a record revenue of C$179.3 million for Q2 FY2026, reflecting a 30% year-over-year increase and surpassing estimates of C$171.15 million, indicating strong performance in the retail sector.
- Stable Market Share: Canna Cabana maintained a 12% market share, and excluding British Columbia's restrictions, its share increased to 14%, up from 13% last year, demonstrating robust growth in a competitive market.
- Improved Profitability: Adjusted EBITDA reached a record C$13.9 million, a 73% year-over-year increase and the fastest growth in nine quarters, despite having three fewer days in the quarter, showcasing effective cost control and operational efficiency.
- Medical Cannabis Distribution Growth: Remexian achieved a record distribution of 7.6 tonnes of medical cannabis in Germany, marking a 49% year-over-year and 21% sequential increase, further solidifying High Tide's position in the international market.
See More
High Tide Reports Strong Q2 Results with Record Revenue
- Record Revenue: High Tide's German medical cannabis subsidiary, Remexian Pharma GmbH, achieved record revenue of $31.6 million in Q2 2026, demonstrating strong growth potential in the medical cannabis market and further solidifying its market position.
- Margin Improvement: Remexian's gross margins increased to 27%, reflecting effective cost control and successful strategies in product pricing and market demand, thereby enhancing overall profitability.
- Positive Free Cash Flow: The company reported positive free cash flow, indicating strong operational efficiency and financial health, which provides funding support for future expansions and investments, boosting investor confidence.
- Financial Transparency: High Tide released unaudited financial statements for the period ending April 30, 2026, ensuring financial transparency and enhancing market trust in its long-term growth strategy.
See More
High Tide Reports Record Revenue and Growth in Q2 2026
- Record Revenue: High Tide achieved a record revenue of CAD 179.3 million in Q2 2026, reflecting a 30% year-over-year increase, marking the fastest growth rate in 11 quarters and demonstrating strong performance in both Canadian and German markets.
- Medical Cannabis Growth: Remexian Pharma GmbH generated record revenue of CAD 31.6 million from medical cannabis sales in Germany, with gross margins increasing to 27%, indicating that the company's market share has now exceeded 14%, laying a solid foundation for future expansion.
- Positive Free Cash Flow: Although free cash flow was CAD 1.5 million, down from CAD 4.9 million last year, the company reported strong operating cash flow of CAD 8.8 million, showcasing its ongoing financial health and growth potential.
- Significant Membership Growth: Cabana Club membership has surpassed 2.65 million, up 39% year-over-year, while ELITE membership reached 178,000, an 84% increase, indicating continued improvement in customer loyalty and market share.
See More
